StockNews.AI
EXEL
StockNews.AI
98 days

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

1. EXEL initiated Phase 1 clinical study for XB628 targeting advanced tumors. 2. This first-in-class therapy may enhance EXEL's oncology portfolio.

2m saved
Insight
Article

FAQ

Why Bullish?

The beginning of clinical trials often leads to positive market sentiment. Historical examples include similar biotech advancements leading to stock price increases.

How important is it?

The news indicates a significant development in EXEL's drug pipeline, which could drive interest and investment.

Why Short Term?

Investors typically react quickly to news of clinical study advancements. This is especially true in biotech stocks where news can trigger immediate trading activity.

Related Companies

INVNBMYMRK
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (.

Related News